Citius Pharmaceuticals' (CTXR) unit Citius Oncology (CTOR) said Tuesday it signed a distribution agreement with Cencora to expand a commercial distribution network for Lymphir, a treatment for relapsed or refractory cutaneous T-cell lymphoma.

Under the agreement, Cencora will operate as a wholesale distributor for the treatment, enhancing access and availability of Lymphir across treatment centers in the US, the company said.

Financial terms of the deal were not disclosed.

CTXR and CTOR shares were up 6.6% and 1.5%, respectively, in recent premarket activity.